Liposomal Annamycin (L-Annamycin) for Soft Tissue Sarcoma

Phase-Based Progress Estimates
The University of Texas MD Anderson Cancer Center, Houston, TXSoft Tissue Sarcoma+1 MoreLiposomal Annamycin (L-Annamycin) - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will study the effects of a new cancer drug called L-Annamycin. The first part of the trial will focus on finding the best dose of the drug, and the second part will focus on whether the drug can shrink tumors.

Eligible Conditions
  • Soft Tissue Sarcoma
  • Lung Metastasis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Cycle 1 Day 1 ( each cycle is 21 days)

21 days
Dose Limiting Toxicity
Day 21
Efficacy of L-Annamycin
Day 21
Area Under the Plasma Concentration Versus Time Curve (AUC) of L-Annamycin

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Liposomal Annamycin (L-Annamycin)
1 of 1

Experimental Treatment

55 Total Participants · 1 Treatment Group

Primary Treatment: Liposomal Annamycin (L-Annamycin) · No Placebo Group · Phase 1 & 2

Liposomal Annamycin (L-Annamycin)
Experimental Group · 1 Intervention: Liposomal Annamycin (L-Annamycin) · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: cycle 1 day 1 ( each cycle is 21 days)

Who is running the clinical trial?

Moleculin Biotech, Inc.Lead Sponsor
5 Previous Clinical Trials
143 Total Patients Enrolled
Robert Shepard, MDStudy DirectorMoleculin Biotech, Inc.
3 Previous Clinical Trials
90 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 14 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Is this pioneering clinical trial a unique endeavor?

"To date, Moleculin Biotech Inc.'s Liposomal Annamycin (L-Annamycin) is only being trialled in 5 cities and 1 country. The initial 2021 drug approval trial was concluded with 55 participants successfully completing the Phase 1 & 2 stages. As of now, a single study has been completed for this medication." - Anonymous Online Contributor

Unverified Answer

How many sites are conducting this research trial?

"There are a total of 5 sites that are signing up patients for this clinical trial, including the Washington University in Saint Louis, Rutgers Cancer Institute of New Jersey in New Brunswick and Sarcoma Oncology Center in Santa Monica. Additionally, two other locations have been identified as potential recruitment centres." - Anonymous Online Contributor

Unverified Answer

Has Liposomal Annamycin (L-Annamycin) been utilized in any prior clinical experiments?

"Currently, only one clinical trial is underway for Liposomal Annamycin (L-Annamycin) with none in Phase 3. These studies are predominantly based around Columbus, Ohio but 5 other medical facilities have begun research into this medication." - Anonymous Online Contributor

Unverified Answer

How many participants have been recruited to join this experiment?

"In order to successfully commence this medical trial, we must enroll 55 qualified participants. Washington University in Saint Louis and Rutgers Cancer Institute of New Jersey are two potential sites for participant recruitment." - Anonymous Online Contributor

Unverified Answer

Is recruitment underway for this clinical experiment?

"According to the details hosted on, this trial is currently enrolling participants. The initial posting date was June 5th 2021 and it has been augmented with new information as recently as August 16th 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.